TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27543364
Drug: Melatonin cream
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin cream 2.5%
Study: 24629911
Drug: Dietary olestra
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary olestra (15 g/day)
Study: 10071177
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of d‐Fenfluramine (d‐Fen)
Study: 10071177
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of Ipsapirone (Ips)
Study: 8868007
Drug: Roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine 150 mg
Study: 2347956
Drug: Ceftriaxone 0.5
Normalized name: CEFTRIAXONE 0.5GM/VIL/LIDOCAIN 1% IJ KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 0.5 g IV without probenecid
Study: 23135
Drug: Chlordiazepoxide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (30 mg orally)
Study: 31404033
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment using the Valeda Light Delivery System, 3 times per week for 3-4 weeks over 1 year.
Study: 31404033
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment
Study: 26497059
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol (Group C)
Study: 15975964
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months
Study: 12874091
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/d) administered in the morning
Study: 16144987
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/d) administered at bedtime
Study: 12874091
Drug: Valsartan administered
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan administered at bedtime
Study: 12874091
Drug: Valsartan administered
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan administered in the morning vs bedtime
Study: 10859151
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet dosing of rosiglitazone
Study: 10859151
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations of rosiglitazone
Study: 8026109
Drug: Fish-oil product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil product with a high percentage of omega-3-polyunsaturated fatty acids (K 85, 6g daily)
Study: 8026109
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (6g daily)
Study: 21183763
Drug: Conventional strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strategy (325 mg aspirin orally and a loading dose of 600 mg clopidogrel)
Study: 10882149
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate therapy
Study: 2858749
Drug: Nightly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly oral formula supplements
Study: 22592929
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg misoprostol vaginally 12 hours before hysteroscopy
Study: 31549577
Drug: Spironolactone, 50
Normalized name: Spironolactone, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 50 mg orally once daily for 12 months
Study: 31549577
Drug: Eplerenone, 50
Normalized name: Eplerenone, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone, 50 mg orally once daily for 12 months
Study: 28686777
Drug: Topical dapsone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dapsone gel, 7.5%
Study: 23663063
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (20 Gy) of Gamma knife radiosurgery
Study: 23663063
Drug: Gamma knife
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma knife radiosurgery (both doses)
Study: 21875223
Drug: Nicotine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (6 mg)
Study: 19819042
Drug: Cinitapride 1mg
Normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride 1mg oral solution t.i.d for 4 weeks
Study: 16415304
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg daily)
Study: 7534166
Drug: Alfuzosin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 7.5 mg/day for 30 days
Study: 31618498
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing Ceratothoa oestroides extract and cefaclor
Study: 31098654
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFA) 2.2 g/day
Study: 29069156
Drug: OTC non-hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC non-hydrogen peroxide bleaching agent (iWhite Instant)
Study: 29069156
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically composed product without active agents)
Study: 25425023
Drug: Zoledronate administration
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate administration after radiotherapy (Group A)
Study: 25425023
Drug: Zoledronate administration
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate administration prior to radiotherapy (Group B)
Study: 16148616
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/day) administered at bedtime
Study: 12680160
Drug: Marimastat 10
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 10 mg b.d. for up to two years
Study: 1796656
Drug: Diclofenac (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (2 x 50 mg daily)
Study: 1796656
Drug: Indomethacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (3 x 25 mg daily)
Study: 6880546
Drug: Regional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional intravenous sympathetic block with guanethidine (RGB)
Study: 30883596
Drug: Carbohydrate intake
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate intake (0.2 g/kg every 15 minutes) during exercise with bananas (Cavendish, Mini-yellow) and a 6% sugar beverage
Study: 20001426
Drug: Synthetic cannabinoids
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic cannabinoids (nabilone, dronabinol, combination of synthetic Delta9‐THC and cannabidiol)
Study: 12884888
Drug: Imipramine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine maintenance treatment (n = 29)
Study: 7838190
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent solution of silver nitrate (n = 929)
Study: 21652616
Drug: i-gel™ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel™ and sILMA™
Study: 12670672
Drug: DMSO 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO 50% applied five times daily to the affected extremity
Study: 12670672
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600mg effervescent tablets three times daily
Study: 8557899
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily)
Study: 15566660
Drug: Sheng Ban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sheng Ban Recipe (SBR) plus common treatment
Study: 7951847
Drug: Omeprazole (OPZ)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OPZ) 20 mg/day
Study: 7951847
Drug: Omeprazole (OPZ)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OPZ) 20 mg/day plus Pirenzepine (PZP) 100 mg/day
Study: 26537478
Drug: L‐T4 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 administered at 0-10 min intervals before breakfast
Study: 26537478
Drug: L‐T4 taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 taken 30 min before breakfast
Study: 27027878
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IGlar) once daily
Study: 23393185
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) Free-Flex
Study: 23393185
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) Forced-Flex
Study: 23393185
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) and Insulin glargine (IGlar)
Study: 18414107
Drug: Bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost/timolol fixed combination (FC)
Study: 15651517
Drug: Morphine 3
Normalized name: apomorphine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 3 mg
Study: 10781460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine 1 microg/kg and morphine 3 mg
Study: 19104775
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 40 mg
Study: 20937127
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg or 200 mg daily
Study: 18538109
Drug: CR002 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR002 (0.3, 1, 3, 10, 30 mg/kg)
Study: 2052306
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (placebo)
Study: 26260705
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin at 1 μg/kg or 2 μg/kg, twice daily for 3 weeks
Study: 26019878
Drug: 80% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% reduced basal insulin dose with reduced prandial bolus insulin and LGI carbohydrate feeding
Study: 31174360
Drug: 100% basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% basal insulin dose
Study: 21228629
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine stored at 2 °C‐8 °C (Group RIX4414_control, n = 171)
Study: 21228629
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine stored at 37 °C for 7 days (Group RIX4414_37 °C, n = 47)
Study: 19480560
Drug: UK-453,061 (non-nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-453,061 (non-nucleoside reverse transcriptase inhibitor)
Study: 17541023
Drug: 17beta‐estradiol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol (0.05 mg/d)
Study: 8852740
Drug: Glucose (isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (isocaloric completed nutritional solution)
Study: 1519576
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg evening dose
Study: 1519576
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg evening dose
Study: 1519576
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg evening dose
Study: 31475415
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day trans‐resveratrol
Study: 15741753
Drug: Satraplatin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satraplatin 100 mg/m² for 5 days plus prednisone 10 mg orally BID
Study: 12393614
Drug: Mitoxantrone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (10 mg/m² per day x 5) and Etoposide (100 mg/m² per day x 5)
Study: 12393614
Drug: Cytarabine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (200 mg/m² per day x 7) and Daunorubicin (45 mg/m² per day x 3)
Study: 10355069
Drug: Cordichin (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordichin (fixed combination of chinidin and verapamil)
Study: 10355069
Drug: Chronic antiarrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antiarrhythmic drug administration (Sotalol or Cordichin)
Study: 10355069
Drug: Antiarrhythmic medication
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic medication (Sotalol or Cordichin)
Study: 25782429
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride application
Study: 20299993
Drug: Intravenous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioids (group O)
Study: 17296819
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate 325 mg three times daily for 8 weeks
Study: 12269969
Drug: Alicaforsen (ISIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen (ISIS 2302) 300 mg, infused intravenously three times a week for 4 weeks
Study: 12269969
Drug: Alicaforsen (ISIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen (ISIS 2302) 350 mg, infused intravenously three times a week for 4 weeks
Study: 12269969
Drug: Alicaforsen (ISIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen (ISIS 2302) 250 mg, infused intravenously for patients weighing 36-50 kg
Study: 10194609
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline formulation (200 mg anhydrous theophylline)
Study: 10194609
Drug: Market formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Market formulation (Theobid)
Study: 8874661
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 200 micrograms twice daily
Study: 28258730
Drug: Alpha Lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Lipoic Acid (ALA) oral supplementation
Study: 26021488
Drug: DHA+EPA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+EPA (4 g/day)
Study: 15871484
Drug: 5-HT2A inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-HT2A inhibitor (sarpogrelate 300 mg/day)
Study: 15871484
Drug: NSAIDs (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (diclofenac 75 mg/day)
Study: 2856892
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg
Study: 6337412
Drug: Nadolol 160
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 160 mg
Study: 7936823
Drug: Protein intakes
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intakes ranging from 2.25 to 3.9 g.kg‐1.d‐1 and energy intakes ranging from 115 to 147 kcal.kg‐1.d‐1
Study: 8204277
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream
Study: 17719167
Drug: L-arginine (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3g daily)
Study: 9167772
Drug: Single-drug parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug parenteral polyestradiol phosphate (240 mg intramuscularly every second week for the first two months, then every fourth week)
Study: 24289108
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg once daily (QD)
Study: 22781199
Drug: Nebulized 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 0.5% salbutamol (150 µg/kg) + 0.025% ipratropium bromide (1 ml) + saline (2 ml)
Study: 14748763
Drug: Dronedarone 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 800 mg
Study: 14748763
Drug: Dronedarone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 1200 mg
Study: 14748763
Drug: Dronedarone 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 1600 mg
Study: 14748763
Drug: Dronedarone (800‐1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone (800‐1600 mg daily) added to metoprolol (200 mg daily)
Study: 11606503
Drug: High-dose UDCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UDCA (20 mg/kg daily)
Study: 9587719
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg plus ketoprofen 100 mg and propacetamol 2 g (group 3)
Study: 2683824
Drug: Nimodipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (2 mg.h‐1)
Study: 24850775
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of 0.2% chlorhexidine (CHX) for 60 s as a rinse
Study: 24850775
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of 0.2% chlorhexidine (CHX) for 60 s as a swab
Study: 24060277
Drug: White lupin
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White lupin fibre (25 g/d)
Study: 24060277
Drug: Soya fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya fibre (25 g/d)
Study: 21288325
Drug: Standard Vietnamese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Vietnamese national guideline treatment for tuberculous meningitis
Study: 21288325
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus high-dose rifampicin and levofloxacin
Study: 15800226
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target international normalized ratio, 2.0 to 3.0)
Study: 8550648
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Morphine and Methylprednisolone
Study: 2191764
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus tamoxifen (RT-TAM)
Study: 16864164
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (RT)
Study: 30088178
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CT)
Study: 2191764
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy or tamoxifen
Study: 30135176
Drug: CAR T-cell
Normalized name: CD123-CD33cCAR T-cells
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T-cell therapy with engineered multispecificity
Study: 25802955
Drug: MT +
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT + MG
Study: 16647411
Drug: intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous immune globulin (IVIg) at 0.8 g/kg
Study: 10966281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iNO and HV
Study: 6407429
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg slow release isosorbide dinitrate (ISDN group)
Study: 6407429
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg slow release nitroglycerin (NTG group)
Study: 27184785
Drug: Ibuprofen IR/ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen IR/ER
Study: 22371525
Drug: Daily electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily electronic transmission of body weight to HF clinic using an electronic scale.
Study: 11032589
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/d
Study: 15699284
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy with tamoxifen
Study: 12818947
Drug: Propofol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (100-200 micro g x kg(‐1) x min(‐1)) with 60% N(2)O in O(2)
Study: 11905407
Drug: Preoperative selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative selective gut decontamination (SGD) with oral nonabsorbable antibiotics (polymyxin B and neomycin) for 5 to 7 days
Study: 8751020
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine (0.03 mg/kg)
Study: 11348713
Drug: Split vaccine
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split vaccine
Study: 24074027
Drug: E2 valerate
Normalized name: valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 valerate (4 mg/day) for 5-12 days
Study: 19696205
Drug: Medical Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutrition Therapy (MNT) program
Study: 17414703
Drug: Antilymphocyte globulin
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte globulin (ALG) induction without steroids
Study: 11528581
Drug: Infrequent monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infrequent monitoring (at baseline and twice yearly)
Study: 9146258
Drug: Collaborative standardization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative standardization of diagnosis and treatment of R/O sepsis patients
Study: 3371082
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g or 10% fructose-1,6-diphosphate (FDP) twice daily for 7 to 10 days